SEMA3G

Across TCGA pan-cancer cohorts, SEMA3G Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SEMA3G data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher SEMA3G Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SEMA3G expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, CESC, and ESCA are the cancer types where SEMA3G Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
CESC	DFS	Median	III,IV	0.156	0.738	<.001	32	view →
ESCA	DFS	Median	II,III,IV	0.159	0.525	.008	30	view →
UCEC	DFS	Median	All	0.955	0.613	.010	18	view →
COAD	OS	Median	IV	0.211	0.655	.034	9	view →
PRAD	DFS	Median	All	0.617	0.886	.038	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.427	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SEMA3G–ACC (DFS)

Open the ACC breakdown →